Sensus Healthcare (NASDAQ:SRTS) CEO Purchases $100,750.00 in Stock

Sensus Healthcare CEO Joseph Sardano purchased 25,000 shares of the company's stock for $100,750, increasing his ownership by 2.13%. The purchase was disclosed in a SEC filing. Sensus Healthcare's stock performance includes a market cap of $66.78 million and a recent quarterly earnings report showing a revenue of $6.88 million. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and an average target price of $8.00.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) CEO Joseph Sardano purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was purchased at an average cost of $4.03 per share, with a total value of $100,750.00. Following the purchase, the chief executive officer owned 1,200,293 shares in the company, valued at $4,837,180.79. This represents a 2.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Get Sensus Healthcare alerts:

Sensus Healthcare Price Performance

SRTS traded up $0.03 during midday trading on Wednesday, hitting $4.07. 48,211 shares of the company's stock traded hands, compared to its average volume of 167,827. The company has a market cap of $66.78 million, a PE ratio of -68.00 and a beta of 1.38. The stock's fifty day simple moving average is $3.42 and its 200-day simple moving average is $4.06. Sensus Healthcare, Inc. has a one year low of $3.03 and a one year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. The company had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.31 million. On average, research analysts expect that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SRTS. IFP Advisors Inc increased its position in Sensus Healthcare by 37.2% during the first quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock worth $89,000 after acquiring an additional 5,100 shares during the period. Kingstone Capital Partners Texas LLC acquired a new stake in Sensus Healthcare in the 2nd quarter worth $3,170,000. Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare during the 1st quarter worth about $542,000. Acadian Asset Management LLC raised its position in shares of Sensus Healthcare by 35.3% during the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock valued at $2,225,000 after buying an additional 122,746 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Sensus Healthcare by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after buying an additional 5,289 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on SRTS. Wall Street Zen upgraded Sensus Healthcare from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Zacks Research upgraded Sensus Healthcare from a "strong sell" rating to a "hold" rating in a report on Wednesday, October 22nd. Lake Street Capital decreased their target price on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Weiss Ratings reissued a "sell (d)" rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Finally, HC Wainwright decreased their price objective on shares of Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sensus Healthcare has a consensus rating of "Hold" and an average target price of $8.00.

Get Our Latest Stock Report on Sensus Healthcare

Sensus Healthcare Company Profile

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Should You Invest $1,000 in Sensus Healthcare Right Now?

Before you consider Sensus Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.

While Sensus Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here